Suzhou, China, March 20, 2026 - Alphamab Oncology (stock code: 9966.HK) today announced that the first patient has been dosed in a phase III clinical study (JSKN016-301) evaluating JSKN016, a novel TROP2/HER3 bispecific antibody-drug conjugate (ADC) for the treatment of triple-negative breast cancer (TNBC). This milestone brings another innovative bispecific ADC from the company's pipeline into pivotal development, reinforcing its potential to offer a more effective and safer treatment option for patients with TNBC.
Breast cancer is the most commonly diagnosed malignancy among women worldwide, with a growing disease burden. TNBC accounts for approximately 15–20% of all breast cancer cases and is characterized by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. This subtype is associated with high invasiveness, increased recurrence rates, and poor prognosis. For patients with locally advanced or metastatic TNBC who have progressed after at least one line of systemic chemotherapy (particularly taxane-based therapy), subsequent treatment options remain limited. Current therapies typically yield objective response rates (ORR) of only 10–20% and median progression-free survival (mPFS) of approximately one to three months, underscoring a significant unmet medical need.
JSKN016 is a bispecific ADC developed by Alphamab Oncology leveraging its proprietary single-domain antibody and bispecific antibody platforms. Designed to co-target TROP2 and HER3, JSKN016 features a homogeneous DAR4 ADC achieved through glycan-specific conjugation. This enables simultaneous blockade of tumor signaling pathways and enhanced intracellular delivery of a topoisomerase I inhibitor for precise and potent antitumor activity. Early-phase clinical studies have demonstrated encouraging antitumor activity and a favorable safety profile of JSKN016 in heavily pretreated advanced TNBC and other solid tumors.
JSKN016-301 is an open-label, randomized, controlled, multicenter phase III trial expected to be conducted at approximately 60 sites across China. The study aims to evaluate the efficacy and safety of JSKN016 versus treatment of physician's choice (TPC) in patients with unresectable locally advanced, recurrent, or metastatic TNBC who have failed at least two lines of systemic therapy. Primary endpoints are progression-free survival (PFS) and overall survival (OS) as assessed by a Blinded Independent Review Committee (BIRC) per RECIST v1.1. Secondary endpoints include investigator-assessed PFS, ORR, disease control rate (DCR), and duration of response (DoR), as well as BIRC-assessed ORR, DCR, and DoR.
About JSKN016
JSKN016 is a TROP2/HER3 targeting bispecific ADC developed using the proprietary single-domain antibody and bispecific antibody platforms. It features a homogeneous DAR4 ADC achieved through glycan-specific conjugation. JSKN016 binds to TROP2 and/or HER3 on tumor cells, blocks the corresponding signaling pathways and releases topoisomerase I inhibitors through cellular endocytosis, thereby exerting potent anti-tumor effects.
JSKN016 has demonstrated promising antitumor activity and a favorable safety profile across multiple solid tumors. Multiple clinical studies of JSKN016 as monotherapy and in combination therapies for lung cancer, breast cancer, and other indications have been initiated. The Phase III clinical study evaluating JSKN016 for the treatment of triple-negative breast cancer (TNBC) is currently ongoing.
About Alphamab Oncology
Alphamab Oncology (Stock Code: 9966.HK) is an innovative biopharmaceutical company focused on oncology. Leveraging proprietary platforms-including single-domain antibodies, bispecific antibodies, glycan-specific conjugation, linker-payloads, dual-payload ADCs, and high-concentration subcutaneous formulations, the Company has built a differentiated and globally competitive pipeline, covering cutting-edge candidates in ADCs, bispecific antibodies, and single-domain antibodies.
One product has received market approval: Envafolimab (KN035, brand name: 恩维达®), the world's first subcutaneously injected PD-(L)1 inhibitor, offering greater convenience and accessibility in cancer treatment. The NMPA has accepted the new drug application for KN026 (Anbenitamab Injection), a HER2 bispecific antibody, for second-line or later HER2-positive gastric cancer. Five bispecific ADC candidates have entered clinical stages, and next-generation ADC pipelines—such as dual-payload ADCs—are advancing rapidly. The Company has established strategic partnerships with organizations including CSPC, ArriVent, and Glenmark, covering both product development and technology platforms.
Our overarching mission is to make cancer manageable and curable by addressing unmet clinical needs in oncology. Alphamab Oncology is continuously dedicated to the development of effective, safe, and globally competitive anti-tumor drugs, enabling patients to achieve long-term, high-quality survival and delivering China-innovated cancer therapies to benefit patients worldwide.
Alphamab Oncology Forward-Looking Statements
This press release contains statements related to our future business，financial performance and future events involving Alphamab Oncology that may constitute forward-looking statements. These statements include projections and estimates and relevant assumptions, statements regarding plans and expectations and statements regarding future activities, operations and performance. These statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," or words of similar meaning. Such statements are based on the certain assumptions of Alphamab Oncology’s management and business operations, which are subject to various risks and uncertainties, including but not limited to political, economic, legal and business environment. The actual results, performance or achievements of Alphamab Oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statements. Unless otherwise required by applicable laws, Alphamab Oncology does not undertake obligation to publicly update any forward-looking statement nor liability for the failure to materialize such forward-looking statements, whether because of new information, future events or otherwise.
Pharmaceutical Information Statements
Alphamab Oncology does not recommend the clinical use of any already approved or under-development drugs/indications. Any information contained in this press release should not be regarded as any drug application, promotion or advertisement.
